<?xml version="1.0" encoding="UTF-8"?>
<ref id="B98-viruses-12-00526">
 <label>98.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>J.W.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>G.Q.</given-names>
   </name>
  </person-group>
  <article-title>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title>
  <source>Int. J. Antimicrob. Agents</source>
  <year>2020</year>
  <comment>in press</comment>
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105954</pub-id>
 </element-citation>
</ref>
